John M. Pezzuto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John M. Pezzuto has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Muriel Cuendet
School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
4 shared publications Carol P. Oteham
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, College of Pharmacy, Nursing, and Health Sciences, Purdue University, West Lafayette, Indiana, USA
2 shared publicationsRichard C. Moon
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, College of Pharmacy, Nursing, and Health Sciences, Purdue University, West Lafayette, Indiana, USA
2 shared publications- Andreas Nievergelt
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Quai Ernest-Ansermet 30, CH-1211 Geneva 4, Switzerland
1 shared publication Paul A. Peaden
Nature's Sunshine Products, Inc., Spanish Fork, Utah, USA
1 shared publicationWilliam J. Keller
Nature's Sunshine Products, Inc., Spanish Fork, Utah, USA
1 shared publication
Latest Publications
- 1 August 2014
- Published by Oxford University Press (OUP)
- p. 52-84
Molecular Targets of Botanicals Used for Chemoprevention
- 1 August 2014
- Published by Oxford University Press (OUP)
- p. 52-84
Molecular Targets of Botanicals Used for Chemoprevention
- 1 January 2008
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 46 (1-2) , 3-7
Dietary Administration ofAsimina triloba.(Paw Paw) Extract Increases Tumor Latency inN.-Methyl-N.-nitrosourea–Treated Rats
- 1 January 2008
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 46 (1-2) , 3-7
Dietary Administration ofAsimina triloba.(Paw Paw) Extract Increases Tumor Latency inN.-Methyl-N.-nitrosourea–Treated Rats
- 27 January 2006
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 69 (3) , 460-463
Quinone Reductase Induction as a Biomarker for Cancer Chemoprevention
Chemoprevention involves the use of natural or synthetic substances to reduce the risk of developing cancer. Strategies for protecting cells from initiation events include decreasing metabolic enzymes responsible for generating reactive species (phase I enzymes) while increasing phase II enzymes that can deactivate radicals and electrophiles known to intercede in normal cellular processes. Reduction of electrophilic quinones by quinone reductase is an important detoxification pathway. Following evaluation of approximately 3000 plant and marine organism extracts, the number characterized as “active” was established in the range of 12% of the total, and over 60 active compounds have been isolated as quinone reductase inducers. One of them, isoliquiritigenin (1), isolated from tonka bean, was shown to be a monofunctional inducer by having similar quinone reductase inducing ability in wild-type Hepa 1c1c7 cells and two mutant cell lines. To further investigate the mechanism of induction, HepG2 human hepatoma cells stably transfected with ARE-luciferase plasmid were used. Isoliquiritigenin (1) significantly induced the luciferase activity in a dose-dependent manner. On the basis of these results, a full-term cancer chemoprevention study was conducted with 7,12-dimethylbenz[a]anthracene (DMBA)-treated female Sprague-Dawley rats. Dietary administration of 1 increased tumor latency. Based on these promising preliminary results, additional mechanistic studies are underway, as well as full-term carcinogenesis studies with chronic administration schedules.
- 27 January 2006
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 69 (3) , 460-463
Quinone Reductase Induction as a Biomarker for Cancer Chemoprevention
Chemoprevention involves the use of natural or synthetic substances to reduce the risk of developing cancer. Strategies for protecting cells from initiation events include decreasing metabolic enzymes responsible for generating reactive species (phase I enzymes) while increasing phase II enzymes that can deactivate radicals and electrophiles known to intercede in normal cellular processes. Reduction of electrophilic quinones by quinone reductase is an important detoxification pathway. Following evaluation of approximately 3000 plant and marine organism extracts, the number characterized as “active” was established in the range of 12% of the total, and over 60 active compounds have been isolated as quinone reductase inducers. One of them, isoliquiritigenin (1), isolated from tonka bean, was shown to be a monofunctional inducer by having similar quinone reductase inducing ability in wild-type Hepa 1c1c7 cells and two mutant cell lines. To further investigate the mechanism of induction, HepG2 human hepatoma cells stably transfected with ARE-luciferase plasmid were used. Isoliquiritigenin (1) significantly induced the luciferase activity in a dose-dependent manner. On the basis of these results, a full-term cancer chemoprevention study was conducted with 7,12-dimethylbenz[a]anthracene (DMBA)-treated female Sprague-Dawley rats. Dietary administration of 1 increased tumor latency. Based on these promising preliminary results, additional mechanistic studies are underway, as well as full-term carcinogenesis studies with chronic administration schedules.
- 1 September 2004
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 3 (9) , 889-890
Resveratrol: A whiff that induces a biologically specific tsunami
- 1 September 2004
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 3 (9) , 889-890
Resveratrol: A whiff that induces a biologically specific tsunami
- 1 June 2002
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 12 (6) , 827-835
Non-steroidal anti-inflammatory drugs in cancer treatment
- 1 June 2002
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 12 (6) , 827-835
Non-steroidal anti-inflammatory drugs in cancer treatment